A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management
Chetty A, Rafi E, Bellini N, Buchholz N, Isaacs D. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management. Endocrine Practice 2023, 30: 292-303. PMID: 38122931, DOI: 10.1016/j.eprac.2023.12.010.Peer-Reviewed Original ResearchConceptsWeight-related complicationsGlucose-dependent insulinotropic polypeptideReceptor agonistsIncretin therapiesGlucagon-like peptide-1Weight managementObesity managementLate-stage developmentOral GLP-1 receptor agonistSide effectsAssociated with weight regainReview clinical trial dataGLP-1 receptor agonistsDual GLP-1/GIP receptor agonistsGLP-1/GIP receptor agonistsWeeks of treatmentGastrointestinal side effectsClinical trial dataLevels of weight lossWeight reductionCombination therapyWeight regainClinical trialsTherapyPeptide-1
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply